Investors – Calliditas Therapeutics AB

Share Price: Sweden

Share Price: US

Interim Report Q3 2021

On November 18, 2021, at 07:00 CET, Calliditas Therapeutics published its interim report for the third quarter 2021.

Read the report

IR Calendar

Feb 24, 2022Year-end report for the period January 1 – December 31, 2021
Mar 1, 2022 - Mar 2, 2022Sachs European Life Sciences CEO Forum
Mar 10, 2022BioCapital Europe 2022

Press releases

Jan 28, 2022Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™
Dec 15, 2021FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
Nov 18, 2021Interim Report Q3, 2021

All press releases